New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 11, 2014
10:43 EDTOREX, END, AMKR, ACHN, ATML, HLT, MTGE, AVNR, PPG, CLSNHigh option volume stocks
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2015
08:19 EDTPPGPPG Industries outlook has improved, says RBC Capital
Subscribe for More Information
November 24, 2015
16:33 EDTHLTHilton eradicating malware in payment cards systems
Subscribe for More Information
November 19, 2015
10:25 EDTATMLOptions with decreasing implied volatility
Subscribe for More Information
08:48 EDTATMLDialog shareholders approve allocation of shares to complete Atmel takeover
Dialog Semiconductor (DLGNF) announced that at an extraordinary general meeting of shareholders held today, the Dialog shareholders have approved the allocation of shares required to complete the company's previously announced acquisition of Atmel Corporation (ATML). The resolution was approved by a vote of 61.94% of the shares represented at the meeting. The transaction remains subject to approval of Atmel's stockholders and other customary conditions. The parties continue to expect completion of the transaction during the first quarter of 2016.
08:47 EDTATMLDialog says resolution in favor of Atmel takeover passed at General Meeting
Subscribe for More Information
November 18, 2015
10:10 EDTATMLOptions with decreasing implied volatility
Options with decreasing implied volatility: INSY PRGO SYF KSS LOCO ATML JWN JD MEG MWE
07:45 EDTHLTHilton management to meet with Deutsche Bank
Meeting to be held in Denver on November 18 hosted by Deutsche Bank.
November 16, 2015
08:07 EDTAVNRConcert Pharmaceuticals achieves $2M milestone from Avanir
Concert Pharmaceuticals (CNCE) announced that it has achieved a $2M milestone under its development and license agreement with Avanir Pharmaceuticals (AVNR) for the progression of the clinical development of AVP-786. The milestone is a result of Avanir initiating dosing of patients in a Phase 3 clinical trial with AVP-786 for the treatment of agitation in patients with Alzheimer's disease. The collaboration agreement between Concert and Avanir provides Avanir with worldwide rights to develop and commercialize AVP-786 and other deuterium-modified dextromethorphan (d-DM) compounds. Under the agreement, Concert is eligible to receive additional milestone payments based upon achievement of certain predefined regulatory and commercial targets. Avanir will continue to have overall responsibility for research, development and commercialization of d-DM compounds, including AVP-786, and Concert is eligible to receive tiered royalties on worldwide sales of any products containing d-DM. The milestone announced today is the third development milestone Concert has earned under this agreement.
08:05 EDTAVNRAvanir initiates Phase III trial of AVP-786
Avanir announced initiation of enrollment into a phase III clinical trial evaluating AVP-786 for the treatment of agitation in patients with Alzheimer's disease. This is the first of two placebo-controlled phase III trials in the company's TRIAD program. Avanir Pharmaceuticals recently received Fast Track designation from the FDA for the development of AVP-786 for this indication. The phase III studies are multicenter, randomized, double-blind, placebo-controlled trials that will evaluate two doses of AVP-786 versus placebo over a period of 12-weeks. Endpoints in these studies will include the Cohen Mansfield Agitation Inventory, the agitation/aggression domain of the Neuropsychiatry Inventory (NPI), other domains of the NPI, measures of global clinical change, and measures of caregiver burden and quality of life. Standard safety measurements will also be performed. TRIAD-1 is expected to enroll approximately 380 patients in 60 centers in the United States. TRIAD-2 is expected to enroll approximately 325 patients in 50 centers in the U.S. and will begin later in 2015. In addition to these two U.S. based trials, there will be additional global trials that will be conducted as part of the TRIAD program. Avanir has also initiated a phase II study to assess the efficacy, safety and tolerability of AVP-786 for the treatment of symptoms associated with residual schizophrenia. This study is expected to enroll approximately 120 patients in the U.S. Additionally, Avanir is currently enrolling patients in a phase II study of AVP-786 for the adjunctive treatment of major depressive disorder. This study began in 2014 and is expected to complete enrollment in 2015.
07:18 EDTHLTDeutsche Bank to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use